Evidence map›Paper›PMID 23695022›Full record

ArticleBritish journal of cancer2013

β-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma.

E Pasquier, J Street, C Pouchy, M Carre, A J Gifford, J Murray, M D Norris, T Trahair, N Andre, M Kavallaris

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02641314 (Phase 2 Trial of Metronomic Treatment in Children and Adolescents With Recurrent or Progressive Neuroblastoma), which is not on this map. Cited by 104 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
104citing papers in PubMed, 4 pooled it
10.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02641314 phase2completednot on this mapstarted 2016, after this paper: background citation

Phase 2 Trial of Metronomic Treatment in Children and Adolescents With Recurrent or Progressive Neuroblastoma (NB)

TypeinterventionalSponsorUniversity of CologneRan2016 to 2023Enrolled18ConditionsRecurrent NeuroblastomaArmsmetronomic therapy
3 · Its place in the literature

Who cites it

104 citing papers in PubMed, 4 syntheses or guidelines pooled it, 158 citations in OpenAlex.

  1. Pooled it
  2. Beta-blocker use and breast cancer outcomes: a meta-analysis.Breast cancer research and treatment · 2024
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

44 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

E PasquierChildren's Cancer Institute Australia, Lowy Cancer Research Centre, UNSW, Randwick, New South Wales 2031, Australia. e.pasquier@ccia.unsw.edu.au
J Street
C Pouchy
M Carre
A J Gifford
J Murray
M D Norris
T Trahair
N Andre
M Kavallaris
Children's Cancer Institute Australia · AUInserm · FRPrince of Wales Hospital · AUUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe use of β-blockers for the management of hypertension has been recently associated with significant clinical benefits in cancer patients. Herein, we investigated whether β-blockers could be used in combination with chemotherapy for the treatment of neuroblastoma.

methodsSeven β-blockers were tested for their antiproliferative and anti-angiogenic properties alone, and in combination with chemotherapy in vitro; the most potent drug combinations were evaluated in vivo in the TH-MYCN mouse model of neuroblastoma.

resultsThree β-blockers (i.e., carvedilol, nebivolol and propranolol) exhibited potent anticancer properties in vitro and interacted synergistically with vincristine, independently of P-glycoprotein expression. β-blockers potentiated the anti-angiogenic, antimitochondrial, antimitotic and ultimately pro-apoptotic effects of vincristine. In vivo, β-blockers alone transiently slowed tumour growth as compared with vehicle only (P<0.01). More importantly, when used in combination, β-blockers significantly increased the tumour regression induced by vincristine (P<0.05). This effect was associated with an increase in tumour angiogenesis inhibition (P<0.001) and ultimately resulted in a four-fold increase in median survival, as compared with vincristine alone (P<0.01).

conclusionβ-blockers can increase treatment efficacy against neuroblastoma, and their combination with chemotherapy may prove beneficial for the treatment of this disease and other drug-refractory cancers.

Indexed as

Abdominal NeoplasmsAdrenergic beta-AntagonistsAngiogenesis InhibitorsAnimalsAntineoplastic Combined Chemotherapy ProtocolsCell ProliferationCells, CulturedDose-Response Relationship, DrugDrug SynergismHumansMiceMice, TransgenicNeovascularization, PathologicNeuroblastomaAdrenergic beta-AntagonistsAngiogenesis Inhibitors

Identifiers

PMID23695022
PMCPMC3694229
OpenAlexW2031937031

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.